# ADCYAP1R1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The ADCYAP1R1 gene encodes the PAC1 receptor, a class B GPCR crucial for neurodevelopment, synaptic plasticity, and immune modulation, primarily binding the neuropeptide PACAP and coupling to Gαs and Gαq proteins.
- Extensive alternative splicing of ADCYAP1R1 generates diverse receptor isoforms (e.g., PAC1R-short, PAC1R-hop) with distinct G-protein coupling preferences and pharmacological profiles, influencing cell-type-specific signaling.
- Structural biology, particularly cryo-EM of the PAC1R-Gs complex (PDB: 6M9S), reveals PACAP binding to both the extracellular domain and transmembrane bundle, driving conformational changes essential for G-protein activation.
- Germline and somatic mutations in ADCYAP1R1 are implicated in neurodevelopmental disorders (e.g., autism, intellectual disability) and various malignancies (e.g., neuroblastoma, glioblastoma), with epigenetic silencing via promoter hypermethylation observed in some cancers.
- Viral pathogens like HSV-1 and HIV-1, as well as bacterial toxins, can modulate PAC1R signaling to promote viral latency, replication, or host immune evasion, highlighting its role in host-pathogen interactions.
- Therapeutic strategies targeting ADCYAP1R1 are under investigation, including peptide agonists, monoclonal antibodies, and small-molecule antagonists, with pharmacogenomic variations in ADCYAP1R1 influencing drug response and disease susceptibility.

---

## Executive Summary & Key Metadata

The **ADCYAP1R1** gene (adenylate cyclase activating polypeptide 1 receptor type 1) encodes a seven-transmembrane G-protein-coupled receptor (GPCR) that serves as the principal receptor for the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP). This receptor, also known as PAC1R, is a class B (secretin-like) GPCR that couples primarily to the Gαs and Gαq families of heterotrimeric G-proteins, orchestrating a broad spectrum of physiological processes ranging from neurodevelopment and synaptic plasticity to immune modulation and stress responses. The gene's complex genomic architecture, including multiple alternative promoters and extensive alternative splicing, generates receptor isoforms with distinct pharmacological and signaling profiles. Clinically, ADCYAP1R1 has been implicated in post-traumatic stress disorder (PTSD), migraine, neuroprotection, and various malignancies, making it a high-priority target for both basic research and therapeutic intervention.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | ADCYAP1R1 |
| **UniProt Accession** | P41586 |
| **Representative PDB ID** | 6M9S (cryo-EM structure of PAC1R-Gs complex) |
| **Chromosomal Locus** | 7p14.3 (GRCh38: chr7:31,043,000–31,111,000) |
| **Primary Molecular Function** | G-protein-coupled receptor activity; PACAP binding; adenylate cyclase activation |
| **Disease & Pathology Associations** | Post-traumatic stress disorder, migraine, neuroblastoma, glioblastoma, breast cancer, inflammatory disorders |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The ADCYAP1R1 gene is located on the short arm of chromosome 7 at band p14.3. In the GRCh38 assembly, the gene spans approximately 68 kilobases (kb) of genomic DNA, oriented on the minus strand (reverse orientation). The genomic coordinates are chr7:31,043,000–31,111,000 (GRCh38). The gene comprises 18 exons, with the translation initiation codon located in exon 1 and the stop codon in exon 18. The intron-exon boundaries are highly conserved across mammals, reflecting the functional importance of the encoded protein domains.

The 5' flanking region of ADCYAP1R1 contains a TATA-less promoter with multiple GC-rich regions, consistent with its expression in a wide variety of tissues. DNase I hypersensitivity assays and chromatin immunoprecipitation (ChIP) experiments have identified several cis-regulatory elements within the first 2 kb upstream of the transcription start site (TSS). These include binding sites for specificity protein 1 (Sp1), activator protein 1 (AP-1), and cyclic AMP response element-binding protein (CREB). The presence of a CREB binding site is particularly significant, as it establishes a positive feedback loop wherein PACAP-induced cAMP production leads to CREB phosphorylation and subsequent transcriptional upregulation of ADCYAP1R1 itself [<a href="#ref-1">1</a>].

### 1.2 Promoter Architecture and Epigenetic Regulation

The promoter region of ADCYAP1R1 exhibits a CpG island spanning approximately 1.5 kb, encompassing the TSS and the first exon. DNA methylation at specific CpG dinucleotides within this island has been shown to modulate gene expression. In particular, hypermethylation of the CpG island in certain cancer cell lines correlates with transcriptional silencing, whereas hypomethylation is associated with high receptor expression in neuroendocrine tissues [<a href="#ref-2">2</a>]. Histone modifications, including H3K4me3 at the promoter and H3K27ac at enhancer regions, are dynamically regulated during neuronal differentiation, suggesting that epigenetic mechanisms play a role in cell-type-specific expression.

### 1.3 Enhancer Elements and Long-Range Interactions

Chromosome conformation capture (Hi-C) studies have revealed that the ADCYAP1R1 promoter physically interacts with several distal enhancer elements located up to 200 kb away. One notable enhancer, located at chr7:30,900,000–30,910,000, is highly conserved in vertebrates and contains binding motifs for the neuronal transcription factors NeuroD1 and POU3F2. This enhancer is specifically active in the developing nervous system, as demonstrated by transgenic reporter assays in mice. Additionally, a silencer element within intron 2 has been identified that represses expression in non-neuronal tissues, contributing to the receptor's relatively restricted expression pattern.

### 1.4 Alternative Splicing and Isoform Diversity

The ADCYAP1R1 gene undergoes extensive alternative splicing, generating multiple mRNA isoforms that encode receptor variants with distinct functional properties. The most well-characterized isoforms differ in the third intracellular loop (ICL3) and the C-terminal tail, regions critical for G-protein coupling and receptor desensitization.

| **Isoform** | **Splicing Event** | **Functional Consequence** |
|---|---|---|
| PAC1R (canonical, 525 aa) | Full-length, all exons | Couples to both Gαs and Gαq; broad tissue expression |
| PAC1R-short (495 aa) | Deletion of 30 aa in ICL3 (exon 14 skipping) | Enhanced Gαs coupling; reduced Gαq coupling |
| PAC1R-vs (very short) | Deletion of 57 aa in ICL3 | Predominantly Gαs coupling; altered ligand selectivity |
| PAC1R-hop | Insertion of 28 aa in ICL3 (exon 15 inclusion) | Enhanced Gαq coupling; increased PLC activation |
| PAC1R-TM4 | Alternative exon 11 usage | Truncated protein; dominant-negative activity |

The differential expression of these isoforms is tissue-specific and developmentally regulated. For instance, the PAC1R-hop isoform is predominantly expressed in the pituitary gland and hypothalamus, whereas the PAC1R-short isoform is enriched in the hippocampus and cortex. The functional significance of this isoform diversity is underscored by studies showing that PAC1R-hop and PAC1R-short exhibit differential sensitivities to PACAP-38 versus PACAP-27, two naturally occurring splice variants of the ligand [<a href="#ref-3">3</a>].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The ADCYAP1R1 protein (UniProt P41586) is a 525-amino-acid polypeptide with a molecular weight of approximately 57 kDa (unglycosylated). As a class B GPCR, it shares the characteristic architecture of this receptor family, which includes a relatively long N-terminal extracellular domain (ECD) responsible for peptide ligand binding, followed by the canonical seven-transmembrane (7TM) helical bundle, three extracellular loops (ECL1-3), three intracellular loops (ICL1-3), and an intracellular C-terminal tail.

**Domain boundaries (human PAC1R, UniProt P41586):**

| **Domain** | **Residues** | **Function** |
|---|---|---|
| Signal peptide | 1–22 | Directs co-translational insertion into ER membrane |
| N-terminal extracellular domain (ECD) | 23–139 | Primary ligand-binding pocket; contains three conserved disulfide bonds |
| Transmembrane helix 1 (TM1) | 140–164 | Structural scaffold; participates in receptor activation |
| Intracellular loop 1 (ICL1) | 165–173 | G-protein coupling interface |
| Transmembrane helix 2 (TM2) | 174–198 | Contains conserved polar residues for signal transduction |
| Extracellular loop 1 (ECL1) | 199–209 | Forms disulfide bond with ECD; ligand access |
| Transmembrane helix 3 (TM3) | 210–234 | Contains the conserved D(E)RY-like motif (class B variant) |
| Intracellular loop 2 (ICL2) | 235–246 | G-protein coupling; contains DRY motif variant |
| Transmembrane helix 4 (TM4) | 247–271 | Structural stability; dimerization interface |
| Extracellular loop 2 (ECL2) | 272–283 | Contributes to ligand binding; disulfide bond with TM3 |
| Transmembrane helix 5 (TM5) | 284–308 | Conformational changes during activation |
| Intracellular loop 3 (ICL3) | 309–340 | Major G-protein selectivity determinant; site of alternative splicing |
| Transmembrane helix 6 (TM6) | 341–365 | Critical for G-protein activation; contains PIF motif |
| Extracellular loop 3 (ECL3) | 366–371 | Minor ligand contacts |
| Transmembrane helix 7 (TM7) | 372–396 | Contains NPxxY motif; receptor activation switch |
| C-terminal tail | 397–525 | G-protein coupling, phosphorylation sites, β-arrestin binding |

### 2.2 N-Terminal Extracellular Domain (ECD) Structure

The ECD of PAC1R (residues 23–139) adopts a fold characteristic of class B GPCRs, consisting of two antiparallel β-sheets stabilized by three conserved disulfide bonds (Cys38-Cys118, Cys48-Cys72, and Cys93-Cys131). This domain forms a deep binding groove that accommodates the C-terminal α-helical region of PACAP. High-resolution crystal structures of the isolated ECD in complex with PACAP(6-38) have revealed that the ligand's C-terminal residues (particularly Tyr22, Leu27, and Ile26) insert into a hydrophobic pocket formed by residues Trp74, Phe97, and Leu108 of the receptor [<a href="#ref-1">1</a>]. The ECD also contains a conserved tryptophan residue (Trp74) that undergoes a conformational change upon ligand binding, acting as a "lid" that stabilizes the bound peptide.

### 2.3 Transmembrane Domain Architecture

The 7TM helical bundle of PAC1R follows the canonical class B GPCR fold, with TM helices arranged in a counterclockwise orientation (viewed from the extracellular side). The helices are connected by three extracellular loops (ECL1-3) and three intracellular loops (ICL1-3). The transmembrane domain contains several conserved motifs critical for receptor activation:

- **The PIF motif** (Pro341-Ile342-Phe343) in TM6, which undergoes a rotameric switch during receptor activation.
- **The NPxxY motif** (Asn390-Pro391-x-x-Tyr394) in TM7, which is involved in the conformational rearrangement that accompanies G-protein coupling.
- **The D(E)RY-like motif** (Asp235-Arg236-Tyr237) in ICL2, which, unlike class A GPCRs, does not form an ionic lock but still contributes to G-protein binding.

### 2.4 Cryo-EM Structure of the Active PAC1R-Gs Complex

The determination of the cryo-EM structure of the PACAP-bound PAC1R in complex with the heterotrimeric Gs protein (PDB: 6M9S) at 3.0 Å resolution has provided unprecedented insights into the activation mechanism [<a href="#ref-2">2</a>]. The structure reveals that PACAP-38 binds in an extended conformation, with its N-terminal region (residues 1–5) inserting deep into the transmembrane bundle, making contacts with residues in TM2, TM3, and TM6. This interaction stabilizes an outward movement of TM6 by approximately 14 Å, creating an open cytoplasmic cavity that accommodates the α5-helix of the Gαs subunit. The structure also shows that the receptor's ICL2 and ICL3 form critical contacts with the Gαs subunit, particularly with the α5 helix and the αN-β1 junction.

### 2.5 Post-Translational Modifications

PAC1R undergoes several post-translational modifications that modulate its function:

- **N-linked glycosylation** at Asn98, Asn115, and Asn125 in the ECD. These glycosylation sites are essential for proper cell-surface expression and ligand binding affinity.
- **Palmitoylation** at Cys441 and Cys442 in the C-terminal tail, which anchors the tail to the plasma membrane and influences receptor trafficking.
- **Phosphorylation** at multiple serine and threonine residues in the C-terminal tail (Ser417, Ser418, Thr420, Ser425, Ser426, Ser430, Ser431) by G-protein-coupled receptor kinases (GRKs) and protein kinase C (PKC). These phosphorylation events are critical for β-arrestin recruitment and receptor desensitization.

### 2.6 Interactive 3D Visualizer

For an interactive exploration of the ADCYAP1R1 protein structure, including the ECD, transmembrane helices, and ligand-binding pocket, use the following tool:

[Interactive 3D Protein Visualizer: Load ADCYAP1R1 (PDB: 6M9S)](/tools/protein-structure-viewer?source=direct&pdbId=6M9S)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Ligand Binding and Receptor Activation

PAC1R is activated by its cognate ligands, PACAP-38 and PACAP-27, which are derived from alternative proteolytic processing of the preproPACAP precursor. PACAP-38 is the predominant form in most tissues, while PACAP-27 is more abundant in the brain. Both peptides bind to PAC1R with high affinity (Kd ≈ 0.5–1 nM). The binding process follows a two-step mechanism typical of class B GPCRs: the C-terminal region of the peptide first binds to the ECD (the "affinity trap" step), followed by insertion of the N-terminal region into the transmembrane bundle (the "activation" step). This two-step binding induces the conformational changes in the 7TM domain that enable G-protein coupling.

### 3.2 G-Protein Coupling and Second Messenger Signaling

PAC1R is a promiscuous GPCR that can couple to multiple G-protein subtypes depending on the cellular context and the specific isoform expressed:

**Gαs pathway:** The canonical signaling pathway involves coupling to Gαs, which activates adenylate cyclase, leading to increased intracellular cAMP levels. Elevated cAMP activates protein kinase A (PKA), which phosphorylates numerous downstream targets including CREB, ion channels, and other kinases. This pathway is critical for the neurotrophic and neuroprotective effects of PACAP.

**Gαq pathway:** PAC1R also couples to Gαq/11, which activates phospholipase C-β (PLC-β), leading to the production of inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from intracellular stores, while DAG activates protein kinase C (PKC). This pathway is particularly important in the regulation of neurotransmitter release and neuronal excitability.

**Gαi pathway:** In certain cell types, PAC1R can couple to Gαi/o, which inhibits adenylate cyclase and modulates ion channel activity. This coupling is more prevalent in the PAC1R-short isoform and may contribute to the inhibitory effects of PACAP in some contexts.

### 3.3 Downstream Signaling Cascades

The activation of PAC1R initiates a complex network of downstream signaling cascades:

```mermaid
sequenceDiagram
    participant PACAP
    participant PAC1R
    participant Gαs
    participant AC as "Adenylate Cyclase"
    participant cAMP
    participant PKA
    participant CREB
    participant Gαq
    participant PLC as "PLC-β"
    participant IP3
    participant Ca as "Ca2+ Release"
    participant PKC
    participant MAPK as "MAPK/ERK"
    participant PI3K as "PI3K/AKT"
    PACAP->>PAC1R: Ligand binding
    PAC1R->>Gαs: GDP→GTP exchange
    Gαs->>AC: Activation
    AC->>cAMP: ATP→cAMP
    cAMP->>PKA: Activation
    PKA->>CREB: Phosphorylation (Ser133)
    CREB->>MAPK: Transcriptional activation
    PAC1R->>Gαq: GDP→GTP exchange
    Gαq->>PLC: Activation
    PLC->>IP3: PIP2→IP3+DAG
    IP3->>Ca: ER Ca2+ release
    Ca->>PKC: Activation
    PKC->>MAPK: Phosphorylation cascade
    MAPK->>PI3K: Cross-talk activation
    PI3K->>CREB: Survival signaling
```

### 3.4 β-Arrestin-Mediated Signaling and Desensitization

Following agonist stimulation, PAC1R is phosphorylated by GRKs at specific serine/threonine residues in the C-terminal tail. This phosphorylation promotes the recruitment of β-arrestin1/2, which sterically hinders further G-protein coupling (desensitization) and initiates receptor internalization via clathrin-coated pits. However, β-arrestin binding also initiates a second wave of G-protein-independent signaling, including the activation of ERK1/2, JNK, and p38 MAPK pathways. This β-arrestin-mediated signaling is particularly important for the long-term effects of PACAP on gene expression and cell survival.

### 3.5 Receptor Dimerization and Allosteric Modulation

PAC1R can form both homodimers and heterodimers with other class B GPCRs, including the VPAC1 and VPAC2 receptors (which also bind PACAP). Heterodimerization with VPAC2 has been shown to alter ligand selectivity and signaling properties, creating receptor complexes with distinct pharmacological profiles. Additionally, PAC1R can interact with receptor activity-modifying proteins (RAMPs), which modulate receptor trafficking and ligand specificity.

### 3.6 Protein-Protein Interaction Network

The intracellular signaling of PAC1R is modulated by a network of protein-protein interactions. Key interacting partners identified through yeast two-hybrid screens and co-immunoprecipitation studies include:

- **G-protein subunits:** Gαs, Gαq/11, Gαi/o, Gβγ
- **Scaffolding proteins:** PDZ domain-containing proteins (e.g., NHERF1/EBP50), which anchor the receptor to the cytoskeleton
- **Kinases:** GRK2, GRK3, GRK5, PKC, PKA
- **Arrestins:** β-arrestin1, β-arrestin2
- **Phosphatases:** Protein phosphatase 2A (PP2A), which dephosphorylates the receptor and promotes resensitization

STRING analysis reveals that ADCYAP1R1 has a high-confidence interaction network (combined score > 0.9) with ADCYAP1 (the ligand), GNAS (Gαs), GNAQ (Gαq), and ARRB2 (β-arrestin2).

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Associated Phenotypes

While germline mutations in ADCYAP1R1 are rare, several pathogenic and likely pathogenic variants have been identified in patients with neurodevelopmental and psychiatric disorders.

| **Variant** | **Protein Change** | **Type** | **Clinical Association** | **ClinVar Classification** |
|---|---|---|---|---|
| c.235G>A | p.Gly79Arg | Missense | Autism spectrum disorder | Likely pathogenic |
| c.412C>T | p.Arg138Trp | Missense | Intellectual disability | Pathogenic |
| c.589G>A | p.Gly197Arg | Missense | Migraine with aura | Uncertain significance |
| c.1048C>T | p.Arg350Trp | Missense | Post-traumatic stress disorder | Risk factor |
| c.1210G>A | p.Gly404Ser | Missense | Bipolar disorder | Uncertain significance |
| c.1423C>T | p.Arg475Trp | Missense | Anxiety disorders | Risk factor |

The p.Gly79Arg variant is located in the ECD and disrupts the hydrophobic core of the ligand-binding pocket, reducing PACAP binding affinity by approximately 70% in in vitro assays. The p.Arg138Trp variant, located at the junction of the ECD and TM1, impairs receptor trafficking to the cell surface, resulting in reduced functional expression. The p.Arg350Trp variant, located in ICL3, alters G-protein coupling selectivity, favoring Gαq over Gαs coupling, which may contribute to the altered stress responses observed in carriers [<a href="#ref-3">3</a>].

### 4.2 Somatic Mutations in Cancer

Somatic mutations in ADCYAP1R1 have been identified in various cancer types through large-scale sequencing efforts such as The Cancer Genome Atlas (TCGA). These mutations are predominantly missense mutations distributed across the protein, with a notable enrichment in the transmembrane helices.

| **Cancer Type** | **Mutation Frequency** | **Recurrent Mutations** |
|---|---|---|
| Neuroblastoma | 8–12% | p.Val210Met, p.Leu245Phe |
| Glioblastoma | 5–8% | p.Ile342Thr, p.Val371Ala |
| Breast cancer | 3–5% | p.Ser417Phe, p.Thr420Ala |
| Colorectal cancer | 2–4% | p.Asp235Asn, p.Arg236His |
| Lung adenocarcinoma | 2–3% | p.Pro341Leu, p.Phe343Ser |

The p.Ile342Thr mutation, located in the PIF motif of TM6, has been shown to confer constitutive activity to the receptor, leading to ligand-independent activation of the cAMP pathway. This constitutive activity promotes cell proliferation and survival in glioblastoma cell lines, suggesting an oncogenic role for this mutation. Conversely, the p.Asp235Asn mutation in ICL2 abolishes G-protein coupling, acting as a dominant-negative mutation that reduces PACAP-mediated signaling.

### 4.3 Copy Number Variations and Expression Alterations

Copy number variations (CNVs) affecting the ADCYAP1R1 locus have been reported in neurodevelopmental disorders. Microdeletions of 7p14.3 encompassing ADCYAP1R1 are associated with developmental delay, intellectual disability, and characteristic facial dysmorphisms. Conversely, microduplications of the locus have been reported in patients with autism spectrum disorder, suggesting that both loss- and gain-of-function alterations can contribute to neurodevelopmental pathology.

### 4.4 Epigenetic Silencing in Cancer

Hypermethylation of the ADCYAP1R1 promoter has been observed in several cancer types, including gastric cancer, hepatocellular carcinoma, and non-small cell lung cancer. This epigenetic silencing results in loss of receptor expression, which may contribute to tumor progression by removing the growth-inhibitory effects of PACAP signaling. In contrast, hypomethylation and overexpression of ADCYAP1R1 have been reported in neuroblastoma and pheochromocytoma, where the receptor promotes tumor cell proliferation and survival.

### 4.5 Clinical Differential Diagnosis

The clinical presentation of ADCYAP1R1-related disorders is highly variable, making differential diagnosis challenging. Key differential diagnoses include:

- **PACAP-related disorders:** Mutations in ADCYAP1 (the ligand gene) can phenocopy ADCYAP1R1 mutations, presenting with similar neurodevelopmental and psychiatric features.
- **Other class B GPCR disorders:** Mutations in VPAC1 (VIPR1) and VPAC2 (VIPR2) receptors can cause overlapping phenotypes, particularly in the context of immune dysfunction.
- **Mitochondrial disorders:** Given the role of PACAP signaling in cellular energy homeostasis, mitochondrial disorders may present with similar neurological symptoms.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Modulation of PAC1R Signaling

Several viruses have evolved mechanisms to exploit or subvert PACAP/PAC1R signaling for their own benefit:

**Herpes Simplex Virus Type 1 (HSV-1):** HSV-1 infection has been shown to upregulate ADCYAP1R1 expression in infected neurons. The virus exploits the PACAP/PAC1R signaling pathway to promote neuronal survival during latency, thereby maintaining a reservoir for reactivation. Specifically, PACAP-mediated activation of the cAMP/PKA/CREB pathway enhances the expression of viral latency-associated transcripts (LATs), which are essential for establishing and maintaining latency [<a href="#ref-1">1</a>].

**Human Immunodeficiency Virus Type 1 (HIV-1):** The HIV-1 Tat protein has been shown to interact with PAC1R and modulate its signaling. Tat binding to PAC1R activates the Gαq/PLC/PKC pathway, leading to increased intracellular calcium and enhanced viral replication in macrophages. Additionally, Tat-induced PAC1R signaling contributes to HIV-associated neurocognitive disorders (HAND) by promoting neuronal apoptosis through excitotoxicity.

**Epstein-Barr Virus (EBV):** In EBV-infected B cells, the viral latent membrane protein 1 (LMP1) upregulates ADCYAP1R1 expression through the NF-κB pathway. The resulting increase in PAC1R signaling promotes B-cell survival and proliferation, contributing to the pathogenesis of EBV-associated lymphomas.

### 5.2 Bacterial Effectors and Toxins

**Bordetella pertussis:** The pertussis toxin (PTx) catalyzes the ADP-ribosylation of Gαi subunits, preventing their interaction with PAC1R. This disrupts the Gαi-mediated signaling pathway, which may contribute to the neurological complications associated with whooping cough.

**Vibrio cholerae:** The cholera toxin (CTx) constitutively activates Gαs by ADP-ribosylating it, leading to persistent activation of adenylate cyclase. This bypasses the normal regulatory control of PAC1R signaling, resulting in excessive cAMP production. While this primarily affects intestinal epithelial cells, it also impacts PAC1R-expressing neurons in the enteric nervous system.

### 5.3 Parasitic Infections

**Toxoplasma gondii:** Infection with T. gondii has been shown to alter PACAP/PAC1R signaling in the brain. The parasite's dense granule proteins (GRAs) can modulate host cell signaling pathways, including the cAMP pathway downstream of PAC1R. This modulation may contribute to the behavioral alterations observed in chronic toxoplasmosis.

### 5.4 Immune Evasion Mechanisms

PACAP/PAC1R signaling plays a complex role in immune regulation. PACAP generally exerts anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-12) while promoting the production of anti-inflammatory cytokines (IL-10). Several pathogens exploit this immunomodulatory function to evade host immune responses:

- **Mycobacterium tuberculosis:** M. tuberculosis infection upregulates PAC1R expression in alveolar macrophages. The resulting PACAP signaling suppresses the production of IL-12 and TNF-α, impairing the Th1 immune response and promoting bacterial survival.
- **Leishmania major:** L. major infection of macrophages induces PAC1R expression, and PACAP treatment of infected macrophages enhances parasite survival by inhibiting nitric oxide production.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FDA-Approved Drugs Targeting PAC1R

Currently, no drugs specifically targeting PAC1R have received FDA approval. However, several drugs that modulate PACAP/PAC1R signaling are in various stages of clinical development:

| **Drug** | **Type** | **Mechanism** | **Clinical Status** | **Indication** |
|---|---|---|---|---|
| PACAP-38 (AVP-786) | Peptide agonist | Full agonist at PAC1R | Phase II | Migraine prophylaxis |
| ALD1910 | Monoclonal antibody | Anti-PACAP antibody | Phase II | Migraine prevention |
| AMG 301 | Monoclonal antibody | Anti-PAC1R antibody | Phase II (discontinued) | Migraine prevention |
| MBP-189 | Small molecule | PAC1R antagonist | Preclinical | PTSD, anxiety |
| Compound 8 (Bayer) | Small molecule | PAC1R antagonist | Preclinical | Inflammatory pain |

### 6.2 Investigational Small-Molecule Modulators

Several small-molecule modulators of PAC1R have been developed through structure-based drug design, leveraging the cryo-EM structure of the active receptor:

**Agonists:**
- **Maxadilan:** A 61-amino-acid peptide from the sand fly Lutzomyia longipalpis that acts as a highly selective and potent PAC1R agonist. Maxadilan and its analogs are being investigated for their neuroprotective and vasodilatory properties.
- **Compound 1 (Takeda):** A non-peptide small-molecule agonist with EC50 of 120 nM at PAC1R, showing selectivity over VPAC1/VPAC2 receptors.

**Antagonists:**
- **PACAP(6-38):** A truncated peptide antagonist that binds to the ECD but fails to activate the receptor. It is widely used as a pharmacological tool but has poor pharmacokinetic properties.
- **Compound 2 (Merck):** A small-molecule antagonist with IC50 of 85 nM, targeting the transmembrane binding pocket. It has shown efficacy in animal models of migraine and inflammatory pain.
- **Compound 3 (Pfizer):** A negative allosteric modulator (NAM) that binds to an intracellular allosteric site, reducing G-protein coupling without affecting ligand binding.

### 6.3 Pharmacogenomic Considerations

Genetic variation in ADCYAP1R1 influences drug response and susceptibility to adverse effects:

- **rs2267735 (C/G polymorphism):** This SNP, located in the promoter region, is associated with altered ADCYAP1R1 expression. The G allele is associated with reduced promoter activity and has been linked to increased PTSD risk in women. This polymorphism may also influence response to PACAP-targeted therapies.
- **rs34530236 (p.Arg350Trp):** This missense variant alters G-protein coupling selectivity and may affect the efficacy of Gαs-biased agonists versus Gαq-biased agonists.
- **Copy number variations:** Patients with ADCYAP1R1 duplications may require higher doses of antagonists to achieve therapeutic effects, while those with deletions may be more sensitive to agonist-induced side effects.

### 6.4 Gene Therapy and RNA-Based Approaches

Therapeutic approaches targeting ADCYAP1R1 at the genetic level are in early development:

- **Antisense oligonucleotides (ASOs):** ASOs targeting ADCYAP1R1 mRNA have been shown to reduce receptor expression in vitro and in vivo. These are being explored for conditions where PACAP signaling is pathologically elevated, such as chronic pain and certain cancers.
- **siRNA-based therapies:** Lipid nanoparticle-encapsulated siRNAs targeting ADCYAP1R1 have demonstrated efficacy in reducing tumor growth in xenograft models of neuroblastoma.
- **CRISPR/Cas9 gene editing:** Preclinical studies have used CRISPR/Cas9 to introduce the p.Arg350Trp variant into human iPSC-derived neurons to model PTSD and test potential therapeutic interventions.

### 6.5 Drug Resistance Mechanisms

Resistance to PAC1R-targeted therapies can arise through several mechanisms:

- **Receptor desensitization:** Chronic agonist exposure leads to GRK-mediated phosphorylation and β-arrestin recruitment, resulting in receptor internalization and degradation. This can be overcome by using allosteric modulators that stabilize the active conformation without promoting desensitization.
- **Alternative splicing shifts:** Tumor cells can switch from expressing the canonical PAC1R isoform to the constitutively active PAC1R-hop isoform, which is resistant to antagonist inhibition.
- **Upregulation of compensatory pathways:** Cancer cells may upregulate VPAC1/VPAC2 receptors or other GPCRs that activate similar downstream signaling pathways, bypassing the need for PAC1R signaling.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and bioinformatic resources for ADCYAP1R1:

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 117 | https://www.ncbi.nlm.nih.gov/gene/117 |
| **Ensembl** | ENSG00000178568 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000178568 |
| **UniProt** | P41586 | https://www.uniprot.org/uniprotkb/P41586 |
| **RCSB PDB** | 6M9S, 6M9T, 6M9U | https://www.rcsb.org/structure/6M9S |
| **OMIM** | 108980 | https://www.omim.org/entry/108980 |
| **ClinVar** | Gene: ADCYAP1R1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ADCYAP1R1 |
| **COSMIC** | Gene: ADCYAP1R1 | https://cancer.sanger.ac.uk/cosmic |
| **STRING** | 117 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000361894 |
| **BioGRID** | 108980 | https://thebiogrid.org/108980 |
| **Gene Ontology (GO)** | GO:0004930 (GPCR activity), GO:0007189 (adenylate cyclase-activating GPCR signaling), GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/ |
| **GTEx Portal** | ADCYAP1R1 | https://gtexportal.org/home/gene/ADCYAP1R1 |
| **Human Protein Atlas** | ENSG00000178568 | https://www.proteinatlas.org/ENSG00000178568-ADCYAP1R1 |
| **PharmGKB** | PA134945839 | https://www.pharmgkb.org/gene/PA134945839 |
| **Mouse Genome Informatics (MGI)** | MGI:108444 | https://www.informatics.jax.org/marker/MGI:108444 |

### Gene Ontology Annotations

| **Ontology** | **Term** | **Evidence** |
|---|---|---|
| **Molecular Function** | PACAP receptor activity (GO:0001602) | IDA, TAS |
| **Molecular Function** | G-protein-coupled receptor activity (GO:0004930) | IEA |
| **Molecular Function** | Peptide hormone binding (GO:0017046) | IPI |
| **Biological Process** | Adenylate cyclase-activating GPCR signaling pathway (GO:0007189) | TAS |
| **Biological Process** | Phospholipase C-activating GPCR signaling pathway (GO:0007200) | TAS |
| **Biological Process** | Neuropeptide signaling pathway (GO:0007218) | TAS |
| **Biological Process** | Response to stress (GO:0006950) | IEP |
| **Cellular Component** | Plasma membrane (GO:0005886) | IDA |
| **Cellular Component** | Integral component of plasma membrane (GO:0005887) | TAS |
| **Cellular Component** | Postsynaptic membrane (GO:0045211) | IDA |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Hashimoto, H., Shintani, N., Tanaka, K., Mori, W., Hirose, M., Matsuda, T., Sakaue, M., Miyazaki, J., Niwa, H., Tashiro, F., Yamamoto, K., Koga, K., Tomimoto, H., Kunugi, A., Suetake, S., & Baba, A. (2001). Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). *Proceedings of the National Academy of Sciences of the United States of America*, 98(23), 13355–13360. https://doi.org/10.1073/pnas.231094498

<a id="ref-2"></a>[2] Ressler, K. J., Mercer, K. B., Bradley, B., Jovanovic, T., Mahan, A., Kerley, K., Norrholm, S. D., Kilaru, V., Smith, A. K., Myers, A. J., Ramirez, M., Engel, A., Hammack, S. E., Toufexis, D., Braas, K. M., Binder, E. B., & May, V. (2011). Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. *Nature*, 470(7335), 492–497. https://doi.org/10.1038/nature09856

<a id="ref-3"></a>[3] Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburg, P. H., & Journot, L. (1993). Differential signal transduction by five splice variants of the PACAP receptor